Glutaminase inhibition can promote leukemia cells to overcome drug resistance, and to be sensitive to BCL2 inhibitors, FMS-like tyrosine kinase 3 and other tyrosine kinase inhibitors (25, 32, 33). This evidence concerns the gene BCL2 and leukemia.